Editorial: Prodrug design and therapeutic applications

Qicai Xiao; Zhengqiu Li; Yanyan Miao; Jiang Xia; Mingyue Wu

doi:10.3389/fphar.2023.1280190

Editorial: Prodrug design and therapeutic applications

Front Pharmacol. 2023 Sep 22:14:1280190. doi: 10.3389/fphar.2023.1280190. eCollection 2023.

Authors

Qicai Xiao^{1

2}, Zhengqiu Li³, Yanyan Miao⁴, Jiang Xia⁵, Mingyue Wu⁶

Affiliations

¹ State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning, China.
² School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou, China.
³ College of Pharmacy, Jinan University, Guangzhou, China.
⁴ School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
⁵ Department of Chemistry, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
⁶ Department of Chemistry, National University of Singapore, Singapore, Singapore.

No abstract available

Keywords: bioavailability; biological activity; prodrug; stimuli-responsive; therapeutic application.

Publication types

Editorial

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work is partly supported by the Natural Science Foundation of Guangdong Province (2021A1515010357) and Shenzhen Science and Technology Program (JCYJ20210324124411032).